2015

/Tag:2015

Oramed Announces Closing of Licensing and Investment Deal with HTIT for Oral Insulin Capsule in China

JERUSALEM, December 29, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a developer of oral drug delivery systems, today announced the closing of its previously-announced license and investment deal with Hefei Tianhui Incubation of Technologies Co. Ltd. ("HTIT"). Oramed has sold 1,155,367 restricted shares [...]

2018-05-30T17:04:16+00:00 Categories: Press Releases|Tags: |

Oramed Signs up to $50 Million Licensing and Investment Agreements for Oral Insulin Capsule in China

Receiving up to $38,000,000 + royalties for licensing deal and $12,000,000 for equity investment at $10.39 per share JERUSALEM, Nov. 30, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it [...]

2018-05-30T17:04:16+00:00 Categories: Press Releases|Tags: |

Oramed to Present at the Aegis Capital Growth Conference

JERUSALEM, October 1, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Aegis Growth Conference, taking place October 7-9, 2015 in Las [...]

2018-05-30T17:04:16+00:00 Categories: Press Releases|Tags: |

Oramed Completes Randomization of Over 50% of Patients in Phase IIb Oral Insulin Study

180 Patients Expected to be Enrolled in Study JERUSALEM, September 9, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that 98 patients have already been enrolled in the Company's [...]

2018-05-30T17:04:17+00:00 Categories: Press Releases|Tags: |

Oramed to Present at the Rodman & Renshaw Global Investment Conference

JERUSALEM, September 4, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Rodman & Renshaw 17th Annual Global Investment Conference, taking place [...]

2018-05-30T17:04:17+00:00 Categories: Press Releases|Tags: |

Sinopharm Capital-Hefei Signs Letter of Intent with Oramed for $50,000,000 Investment and Licensing Deal in China

JERUSALEM, July 7, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has signed a non-binding Letter of Intent (LoI) for an investment and license agreement in China [...]

2018-05-30T17:04:19+00:00 Categories: Press Releases|Tags: |

Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study

Company's largest study to date with over 30 clinical sites in the United States to participate JERUSALEM, June 30, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical Company focused on the development of oral drug delivery systems, announced today that the [...]

2018-05-30T17:04:19+00:00 Categories: Press Releases|Tags: |

Oramed Granted Patent in Russia for Oral Administration of GLP-1

JERUSALEM, June 16, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a developer of oral drug delivery systems, announced today that the Russian Federal Service for Intellectual Property has granted the Company a patent for its invention, titled "Methods and Compositions for Oral Administrations [...]

2018-05-30T17:04:20+00:00 Categories: Press Releases|Tags: |